Hope Against Alzheimer's: Experimental Drug Halves Dementia Risk in Genetically Predisposed Individuals

An international study led by Washington University in St. Louis has found that an experimental anti-amyloid drug can reduce the risk of developing dementia by 50% in individuals with genetic mutations that predispose them to early-onset Alzheimer's. In a subgroup of participants who began treatment symptom-free and continued it for eight years, a significant delay in symptom onset was observed. These findings support the amyloid hypothesis, suggesting that removing amyloid plaques from the brain years before symptoms emerge could delay or even prevent the disease.Although the drug gantenerumab has been discontinued, other similar treatments are in development, offering new hope in the fight against Alzheimer's.​ScienceDaily

Full article: ScienceDaily​